Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

What happened

Annovis Bio received a notice from the NYSE on October 29, 2026, saying it is no longer in compliance with continued listing standards. Its 30 trading-day average market value was about $48.4 million, below the $50 million rule, while stockholders' equity was also below $50 million.

Confirmed

Global impact / market context

Falling below the NYSE's $50 million market value and equity thresholds puts Annovis at risk of being delisted, which means its shares could stop trading on the exchange. To avoid that, the company must submit a plan for regaining compliance.

Analyst inference

The notice does not affect Annovis' operations, reporting duties, or debt agreements, the company said. Still, a low market value reflects weak investor support for a clinical-stage drug developer that is not yet selling a product and depends on outside funding.

Analyst inference

What to watch

1. Annovis said it will submit a plan within 45 days of the notice, telling the NYSE what definitive action it has taken or is taking to regain compliance with listing rules. Confirmed
2. Watch whether the NYSE accepts the plan and gives the company time to fix its market value and stockholders' equity, or moves toward delisting procedures. Analyst inference
3. Watch whether Annovis raises new money or restructures its balance sheet, since higher equity or market value would help it meet the NYSE thresholds. Analyst inference

Evidence

• globenewswire.com